Overview

PD-1 Antibody（Tislelizumab） Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection

Status:
Recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to observe the effect of PD-1 Antibody（Tislelizumab） Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Antibodies
Capecitabine